Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Krebs Biochemicals & Industries
Small Cap•202 Employees•IPO 1994
Current Price
₹52.51
-1.39 (-2.58%)Updated
Today's Range
₹51.20
₹53.90
₹52.51
52 Week Range
52W Low₹53.05
52W High₹113.50
₹52.51
Downside-1.02%
Upside116.15%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹124.21 Cr
Market Cap
Total market value of companyP/E Ratio
-
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
83.58
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹-10.60
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
-235.95%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
-30.10%
ROCE
Return on Capital Employed. >15% is goodNet Margin
-99.30%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
-%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
-1.94%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
-57.50%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
-2.90%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
32.13
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹1.04
Book Value
Net asset value per shareDividend Yield
-%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
72.70%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
1 points- •The company benefits from a high promoter holding of 72.74%, which has remained consistent, signaling strong confidence and long-term commitment from the management in the company's future.
Weaknesses
5 points- •The company exhibits severe financial distress with a negative book value of -67.80, indicating a significant erosion of shareholder equity and a precarious balance sheet position.
- •Profitability is a major concern, with a negative ROCE of -30.10% and OPM of -41.60%, reflecting deep operational inefficiencies and consistent inability to generate profits.
Opportunities
2 points- •Operating in the Pharmaceuticals sector, the company could potentially benefit from the industry's inherent long-term growth trends and consistent demand for healthcare products.
- •A strategic turnaround or product diversification within the pharmaceutical industry could unlock significant value, especially given the current low market valuation.
Threats
4 points- •The company faces intense competition from well-established and financially robust peers in the Pharmaceuticals sector, making market share recovery and growth extremely challenging.
- •Continued operational losses and declining sales pose a significant threat of liquidity crunch, potentially hindering debt servicing and future investment capabilities.
Segment-wise Financial Analysis
Financial Results
Balance Sheet
Standalone • Annual • All amounts in ₹ Crores • CA Schedule III Format
No Balance Sheet Data Available
Standalone annual data is not available for this symbol.
Try switching to Consolidated view.
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
No insider trading data available
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹59.27 | +₹6.76 | +12.88% |
| R3 | ₹56.57 | +₹4.06 | +7.74% |
| R2 | ₹55.24 | +₹2.73 | +5.19% |
| R1 | ₹53.87 | +₹1.36 | +2.60% |
| PIVOT | ₹52.54 | 0.03 | 0.05% |
| CURRENT | ₹52.51 | - | - |
| S1 | ₹45.77 | -₹6.74 | -12.83% |
| S2 | ₹48.47 | -₹4.04 | -7.69% |
| S3 | ₹49.84 | -₹2.67 | -5.09% |
| S4 | ₹51.17 | -₹1.34 | -2.55% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume-92.1% vs avg
0.01L
(04 Mar 2026)Delivery %+18.4% vs avg
96.1%
(04 Mar 2026)Avg Volume (20D)20-day average
0.10L
(04 Feb - 04 Mar)Avg Delivery %Trend ↑
77.7%
(04 Feb - 04 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Alpa Laboratories Ltd
131.00 %
Highest Dividend Yield
Bal Pharma Ltd
1.58 %
Peer Comparison
| Company Name |
|---|
 Alpa Laboratories Ltd |
 Bal Pharma Ltd |
 Par Drugs & Chemicals Ltd |
 Sun Pharmaceutical Industries Ltd |
 Vaishali Pharma Ltd |
About
Krebs Biochemicals & Industries Ltd
Krebs Biochemicals & Industries Limited (KrebsBIO) is an Indian company primarily focused on the manufacturing and sale of Active Pharmaceutical Ingredients (APIs). Their core business revolves around developing and producing key components used in various pharmaceutical formulations. The company's expertise lies in utilizing biotechnological processes to create these APIs, extending their reach beyond medicine into agricultural and industrial applications.
A significant portion of KrebsBIO's product portfolio consists of APIs used in cholesterol management and steroid synthesis. Specifically, they manufacture androstenedione, lovastatin, and simvastatin, all vital components in medications aimed at lowering cholesterol levels. These products highlight their capabilities in producing complex molecules with therapeutic value.
Beyond cholesterol-focused APIs, KrebsBIO develops and offers a diverse range of other pharmaceutical ingredients. This includes amlodipine (used in anti-hypertension medications), cetirizine (an anti-histamine), orlistat (an anti-obesity drug), serratiopeptidase (an anti-inflammatory agent), telmisartan (another anti-hypertension medication), and phenylephrine (commonly found in cold and cough remedies). This broad spectrum showcases their versatility and ability to cater to various therapeutic areas.
In addition to its own product development and manufacturing, KrebsBIO actively participates in contract manufacturing services. This allows them to provide their manufacturing expertise to larger pharmaceutical and multinational companies, offering a valuable outsourcing solution for the production of APIs. This aspect diversifies their revenue streams and strengthens their position within the pharmaceutical industry.
Established in 1991 and headquartered in Visakhapatnam, India, KrebsBIO has a long history of contributing to the pharmaceutical sector. Their combination of in-house API production, biotechnological process development, and contract manufacturing capabilities positions them as a significant player in the Indian pharmaceutical landscape and a potential supplier to global markets.
COMPANY FACTS - KREBSBIO
Registered Address
Plot No.34, 8-2-577/B,, 3rd Floor, Maas Heights,, Road No.8, Banjara Hills,
Hyderabad
TELANGANA
IN
Tel: 914066808040
Website:http://krebsbiochem.com
Investor Relations:http://krebsbiochem.com/krebs.php?id=35&title=Contact-Investor-Relations
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 202
IPO Date: 02/03/1994
MANAGEMENT - KREBSBIO
Dr. R. Ravi
Non-Executive Chairman of the Board
Mr. Ritesh Jain
Chief Financial Officer
Mr. Rakesh Kalbate
Compliance Officer, Company Secretary
Mr. Pabitra Bhattacharya
Managing Director, Additional Director
Mr. Avinash Ravi
Non-Executive Director
Mr. Jitendra Shah
Non-Executive Director
Mr. Satya Chigurupati
Additional Independent Director
Mr. Sumanth Karlapudi
Additional Independent Director
Mr. Popatlal Kathariya
Additional Independent Director
Ms. Dipti Shah
Additional Independent Director
Mr. Satish Khivsara
Non-Executive Independent Director
Investor Questions Answered
Krebs Biochemicals & Industries Ltd (KREBSBIO) Stock FAQs
Get answers to the most common questions about Krebs Biochemicals & Industries Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Krebs Biochemicals & Industries Ltd (KREBSBIO) is ₹52.51. Today, the stock has declined by ₹1.39 (2.58%), trading in a range of ₹51.2 to ₹53.9. The stock opened at ₹53.9 with a trading volume of 802 shares.
Krebs Biochemicals & Industries Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹124.21 crores, P/E ratio of 0.00, ROE of -235.95%, and ROCE of -30.10%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Krebs Biochemicals & Industries Ltd (KREBSBIO) is ₹113.5, while the 52-week low is ₹53.05. Currently trading at ₹52.51, the stock is -0.9% away from its 52-week low and 53.7% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Krebs Biochemicals & Industries Ltd stock at ₹52.51 depends on multiple factors. The stock is currently trading with a P/E ratio of 0.00 and P/B ratio of N/A. Today's performance shows a loss of 2.58%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Krebs Biochemicals & Industries Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹52.51, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Krebs Biochemicals & Industries Ltd's key financial metrics include: P/E Ratio: 0.00, P/B Ratio: N/A, ROE: -235.95%, ROCE: -30.10%, Dividend Yield: 0.00%, EPS: ₹-10.60, Book Value: ₹1.04, Debt-to-Equity: 32.13, and Current Ratio: N/A. The company's market cap stands at ₹124.21 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Krebs Biochemicals & Industries Ltd stock opened at ₹53.9 and is currently trading at ₹52.51, showing a decline of ₹1.39 (2.58%). The intraday high is ₹53.9 and low is ₹51.2. The trading volume stands at 802 shares, indicating moderate market participation today.
Krebs Biochemicals & Industries Ltd has a Price-to-Earnings (P/E) ratio of 0.00, which means investors are willing to pay ₹0.00 for every ₹1 of earnings. With an EPS of ₹-10.60, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
Krebs Biochemicals & Industries Ltd has a market capitalization of ₹124.21 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹52.51) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Krebs Biochemicals & Industries Ltd has a book value of ₹1.04 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹52.51, which is 4949.0% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Krebs Biochemicals & Industries Ltd has a Return on Equity (ROE) of -235.95% and Return on Capital Employed (ROCE) of -30.10%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Krebs Biochemicals & Industries Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Krebs Biochemicals & Industries Ltd has a debt-to-equity ratio of 32.13, which measures the company's financial leverage by comparing total debt to shareholders' equity. A ratio above 2 indicates high leverage and potentially higher financial risk. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Krebs Biochemicals & Industries Ltd has an Earnings Per Share (EPS) of ₹-10.60, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹52.51 and P/E ratio of 0.00, investors are paying 0.00 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Krebs Biochemicals & Industries Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Krebs Biochemicals & Industries Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Krebs Biochemicals & Industries Ltd stock, consider: 1) Fundamental Analysis - Review P/E (0.00), ROE (-235.95%), debt-to-equity (32.13), and growth rates. 2) Technical Analysis - Check 52-week range (₹53.05 - ₹113.50), moving averages, and chart patterns. 3) Valuation - Compare current price (₹52.51) with book value (₹1.04) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Krebs Biochemicals & Industries Ltd share is ₹10.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹52.51 is 425x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Krebs Biochemicals & Industries Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹53.05 - ₹113.50). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 32.13 indicates leverage. 4) Liquidity Risk - Based on trading volume of 802 shares. 5) Valuation Risk - P/E of 0.00 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Krebs Biochemicals & Industries Ltd operates in the industry with key metrics: P/E ratio of 0.00, ROE of -235.95%, market cap of ₹124.21 crores, and dividend yield of 0.00%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 32.13), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Krebs Biochemicals & Industries Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹52.51, with a 52-week range of ₹53.05 to ₹113.50. Based on fundamentals like P/E (0.00), ROE (-235.95%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Krebs Biochemicals & Industries Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹52.51. 2) Fundamental Deterioration - Declining ROE (currently -235.95%), increasing debt (D/E: 32.13), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Krebs Biochemicals & Industries Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.00%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu